Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program

Diagnostic Microbiology and Infectious Disease

Volumn 65, Issue 1, 2009, Pages 27-34

  Pfaller, Michael A ^a,b   Boyken, Linda ^a   Hollis, Richard J ^a   Kroeger, Jennifer ^a   Messer, Shawn A ^a   Tendolkar, Shailesh ^a   Diekema, Daniel J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Candida; Fluconazole; Surveillance; Voriconazole

Indexed keywords

FLUCONAZOLE; VORICONAZOLE;

ACCURACY; ANALYTICAL ERROR; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLINICAL PROTOCOL; CONTROLLED STUDY; DISK DIFFUSION; DRUG SURVEILLANCE PROGRAM; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RELIABILITY;

ANTIFUNGAL AGENTS; CANDIDA; DIAGNOSTIC ERRORS; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; QUALITY ASSURANCE, HEALTH CARE; SENSITIVITY AND SPECIFICITY; TRIAZOLES;

EID: 68249095927     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.05.007     Document Type: Article

References (50)

1. Almirante B., Rodriguez D., Park B.J., Cuenca- Estrella M., Planes A.M., Almela M., Mensa J., Sanchez F., Ayats J., Gimenez M., Sabolls P., Fridkin S.K., Morgan J., Rodriguez-Tudela J.L., Warnock D.W., Pahissa A., and and the Barcelona Candidemia Project Study Group. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from a population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43 (2005) 1829-1835
2. Arendrup M.C., Fuursted K., Gahrn- Hansen B., Schonheyden H.C., Knudsen J.D., Jensen I.M., Bruun B., Christensen J.J., and Johansen H.K. Semi- national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin. Microbiol. Infect. 14 (2008) 487-494
3. Asmundsdottir L.R., Erlendsdottir H., and Gottfredsson M. Increasing incidence of candidemia: results from a 20- year nationwide study in Iceland. J. Clin. Microbiol. 40 (2002) 3489-3492
4. Bronzwaer S., Buchholz U., Courvalin P., Snell J., Cornaglia G., deNeeling A., Aubry- Damon H., Degener J., and EARSS participants. Comparability of antimicrobial susceptibility test results from 22 European counties and Israel: an external quality assurance exercise of the European Antimicrobial Resistance Surveillance System (EARSS) in collaboration with the United Kingdom National External Quality Assurance Scheme (UK NEQAS). J. Antimicrob. Chemother. 50 (2002) 953-964
5. Chaitram J.M., Jevitt L.A., Lary S., Tenover F.C., and The WHO Antimicrobial Resistance Group. The World Health Organizations external quality assurance system proficiency testing program has improved the accuracy of antimicrobial susceptibility testing and reporting among participating laboratories using NCCLS methods. J. Clin. Microbiol. 41 (2003) 2372-2377
6. Clinical and Laboratory Standards Institute (CLSI). Method for antifungal disk diffusion susceptibility testing of yeasts; approved standard, M44-A (2004), CLSI, Wayne, PA
7. Clinical and Laboratory Standards Institute (CLSI). Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints, and quality control limits for antifungal disk diffusion susceptibility testing of yeasts: informational supplement (M44-S2) (2007), CLSI, Wayne, PA
8. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard-third edition, M27-A3 (2008), CLSI, Wayne, PA
9. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts: informational supplement-third edition, M27-S3 (2008), CLSI, Wayne, PA
10. Collins C.D., Eschenauer G.A., Salo S.L., and Newton O.W. To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemias. J. Clin. Microbiol. 45 (2007) 1884-1888
11. Diekema D.J., Messer S.A., Hollis R.J., Boyken L., Tendolkar S., Kroeger J., Jones R.N., and Pfaller M.A. A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp. Diagn. Microbiol. Infect. Dis. 63 (2009) 233-236
12. Hageman J.C., Fridkin S.K., Mohammed J.M., Steward C.D., Gaynes R.P., Tenover F.C., National Nosocomial Infections Surveillance, and (NNIS) System Hospitals. Antimicrobial proficiency testing of National Nosocomial Infections Surveillance System hospital laboratories. Infect. Control. Hosp. Epidemiol. 24 (2003) 356-361
13. Hajjeh R.A., Sofair A.N., Harrison I.H., Lyon G.M., Arthington- Skaggs B.A., Mirza S.A., Phelan M., Morgan J., Lee-Yang W., Ciblak M.A., Benjamin L.E., Sanza L.T., Huie S., Yeo S.F., Brandt M.E., and Warnock D.W. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42 (2004) 1519-1527
14. Hazen K.C., and Howell S.A. Candida, Cryptococcus, and other yeast of medical importance. In: Murray P.R., Baron E.J., Jorgensen J.H., Landry M.L., and Pfaller M.A. (Eds). Manual of clinical microbiology. 9th ed. (2007), ASM Press, Washington, DC 1762-1788
15. Hazen K.C., Baron E.J., Colombo A.L., Girmenia C., Sanchez- Souza A., del Palacio A., de Bedout C., Gibbs D.L., and Global Antifungal Surveillance Group. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J. Clin. Mircobiol. 41 (2003) 5623-5632
16. Henwood C.J., Warner M., Wright P., Johnson A.P., George R.C., and Livermore D.M. Accuracy of routine susceptibility testing of Streptococcus pneumoniae in England and Wales. J. Antimicrob. Chemother. 47 (2001) 893-905
17. Henwood C.J., Livermore D.M., James D., Warner M., and the Pseudomonas Study Group. Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disk susceptibility test. J. Antimicrob. Chemother. 47 (2001) 789-799
18. Jones M.J., Thornsberry C., and Sahm D.F. The Surveillance Network™ (TSN™)-a powerful weapon in the fight against antibiotic resistance. Clin. Laboratory. 44 (1998) 961-963
19. Kahlmeter G., and Brown D.F.J. Resistance surveillance studies- comparability of results and quality assurance of methods. J. Antimicrob. Chemother. 50 (2002) 775-777
20. King A., and Brown D.F.J. Quality assurance of antimicrobial susceptibility testing by disc diffusion. J. Antimicrob. Chemother. 48 Suppl S1 (2001) 71-76
21. Klingspor L., Tornquist E., Johansson A., Petrini B., Forsum U., and Hedin G. A prospective epidemiological survey of candidaemia in Sweden. Scand. J. Infect. Dis. 36 (2004) 52-55
22. Livermore D.M., Macgowan A.P., and Wale M.C.J. Surveillance of antimicrobial resistance: centralized surveys to validate routine data offer a practical approach. BMJ 317 (1998) 614-615
23. Livermore D.M., Threfall E.J., Reacher M.H., Johnson A.P., James D., Cheastry T., Shah A., Warburton F., Swan A.V., Skinner J., Graham A., and Speller D.C.E. Are routine sensitivity test data suitable for the surveillance of resistance? Resistance notes amongst Escherichia coli from blood and CSF from 1991-1997, as assessed by routine and centralized testing. J. Antimicrob. Chemother. 45 (2000) 205-211
24. Lockhart S.R., Messer S.A., Pfaller M.A., and Diekema D.J. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J. Clin. Microbiol. 46 (2008) 2659-2664
25. Lockhart S.R., Messer S.A., Pfaller M.A., and Diekema D.J. Identification and susceptibility profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates. J. Clin. Microbiol. 47 (2009) 242-244
26. Meis J., Petrou M., Bille J., Ellis D., Gibbs D., and the Global Antifungal Surveillance Group. A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagn. Microbiol. Infect. Dis. 36 (2000) 215-223
27. Ostrosky- Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., Powderly W.G., Hyslop N., Kauffman C.A., Cleary J., Mangino J.E., and Lee J. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents. Chemother. 47 (2003) 3149-3154
28. Pappas P.G., Rex J.H., Lee J., Hamill R.J., Larsen R.A., Powderly W., Kauffman C.A., Hyslop N., Mangino J.E., Chapman S., Horowitz H.W., Edwards J.E., and Dismukes W.E. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37 (2003) 634-643
29. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., Edwards J.E., and the Infectious Diseases Society of America. Guidelines for the treatment of candidiasis. Clin. Infect. Dis. 38 (2004) 161-189
30. Peman J., Canton E., and Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multi-centre study in Spain. Eur. J. Clin. Microbiol. Infect. Dis. 24 (2005) 23-30
31. Pfaller M.A., and Diekema D.J. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. Microbiol. 40 (2002) 3551-3557
32. Pfaller M.A., and Diekema D.J. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 10 Suppl 1 (2004) 11-23
33. Pfaller M.A., and Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20 (2007) 133-163
34. Pfaller M.A., Messer S.A., Boyken L., Hollis R.J., Rice C., Tendolkar S., and Diekema D.J. In vitro activities of voriconazole, posaconazole, and fluconazole against 2,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS Global Antifungal Surveillance Program. Diagn. Microbiol. Infect. Dis. 48 (2004) 201-205
35. Pfaller M.A., Hazen K.C., Messer S.A., Boyken L., Tendolkar S., Hollis R.J., and Diekema D.J. Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 42 (2004) 3607-3612
36. Pfaller M.A., Diekema D.J., Rinaldi M.G., Barnes R., Hu B., Veselov A.V., Tiraboschi N., Nagy E., Gibbs D.L., and the Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J. Clin. Microbiol. 43 (2005) 5848-5859
37. Pfaller M.A., Boyken L., Messer S.A., Tendolkar S., Hollis R.J., and Diekema D.J. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 43 (2005) 5208-5213
38. Pfaller M.A., Diekema D.J., and Sheehan D.J. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19 (2006) 435-447
39. Pfaller M.A., Diekema D.J., Rex J.H., Espinel- Ingroff A., Johnson E.M., Andes D., Chaturvedi V., Ghannoum M.A., Odds F.C., Rinaldi M.G., Sheehan D.J., Troke P., Walsh T.J., and Warnock D.W. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44 (2006) 819-826
40. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Meis J.F., Gould I.M., Fu W., Colombo A.L., Rodriguez- Noriega E., and the Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45 (2007) 1735-1745
41. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Bijie H., Dzierzanowskea D., Klimko N.N., Letscher-Bru V., Lisalova M., Muehlethaler K., Rennison C., Zaidi M., and the Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997-2007: 10.5-year analysis of susceptibilities of non-Candida yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 47 (2009) 117-123
42. Poikonen E., Lyytikainen O., Anttila V.J., and Ruutu P. Candidemia in Finland, 1995- 1999. Emerg. Infect. Dis. 9 (2003) 985-990
43. Potz N.A.C., Mushtaq S., Johnson A.P., Henwood C.J., Walker R.A., Varey E., Warner M., James D., and Livermore D.M. Reliability of routine disc susceptibility testing by the British Society for Antimicrobial Chemotherapy (BSAC) method. J. Antimicrob. Chemother. 53 (2004) 729-738
44. Pujol C., Pfaller M., and Soll D.R. Ca3 fingerprinting of Candida albicans bloodstream isolates from the United States, Canada, South America, and Europe reveals a European clade. J. Clin. Microbiol. 40 (2002) 2729-2740
45. Pujol C., Pfaller M.A., and Soll D.R. Flucytosine resistance is restricted to a single genetic clade of Candida albicans. Antimicrob. Agents. Chemother. 48 (2004) 262-266
46. Rees J.R., Pinner R.W., Hajjeh R.A., Brandt M.E., and Reingold A.L. The epidemiological features of invasive mycotic infections in the San Francisco Bay Area, 1992-1993: results of a population- based laboratory active surveillance. Clin. Infect. Dis. 27 (1998) 1138-1147
47. Sandven P., Bevanger L., Digranes A., Haukland H.H., Mannsaker T., and Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. J. Clin. Microbiol. 44 (2006) 1977-1981
48. Snell J.J.S., and Brown D.F.J. External quality assessment of antimicrobial susceptibility testing in Europe. J. Antimicrob. Chemother. 47 (2001) 801-810
49. Tenover F.C., Mohammed M.J., Stelling J., O' Brien T., and Williams R. Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing. J. Clin. Microbiol. 39 (2001) 241-250
50. Tortorano A.M., Kibbler C., Peman J., Bernhardt H., Klingspor L., and Grillot R. Candidemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents. 27 (2006) 359-366